A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome
Latest Information Update: 07 May 2024
At a glance
- Drugs Vosaroxin (Primary) ; Azacitidine; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 30 Apr 2024 Status changed from active, no longer recruiting to completed.
- 23 Mar 2022 Planned End Date changed from 31 Dec 2021 to 29 Apr 2024.
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association